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ABSTRACT
The MYB proto-oncogene is expressed in most
estrogen receptor-positive (ERa+) breast tumors
and cell lines. Expression of MYB is controlled, in
breast cancer and other cell types, by a transcrip-
tional pausing mechanism involving an attenuation
site located 1.7 kb downstream from the transcrip-
tion start site. In breast cancer cells, ligand-bound
ERa binds close to, and drives transcription beyond
this attenuation site, allowing synthesis of complete
transcripts. However, little is known, in general,
about the factors involved in relieving transcriptional
attenuation, or specifically how ERa coordinates
such factors to promote transcriptional elongation.
Using cyclin dependent kinase 9 (CDK9) inhibitors,
reporter gene assays and measurements of total
and intronic MYB transcription, we show that func-
tionally active CDK9 is required for estrogen-
dependent transcriptional elongation. We further
show by ChIP and co-immunoprecipitation studies
that the P-TEFb complex (CDK9/CyclinT1) is re-
cruited to the attenuation region by ligand-bound
ERa, resulting in increased RNA polymerase II Ser-2
phosphorylation. These data provide new insights
into MYB regulation, and given the critical roles of
MYB in tumorigenesis, suggest targetingMYB elong-
ation as potential therapeutic strategy.
INTRODUCTION
The proto-oncogeneMYB (c-MYB), which belongs to the
myb family of transcription factors, has emerged as an
important regulator of cell growth, survival and differen-
tiation during hematopoiesis (1). In certain forms of ag-
gressive leukemia, such as in MLL-associated leukemia,
MYB has been shown to play critical roles in leukemogen-
esis (2,3). Besides its critical role in hematopoiesis and
leukemia, MYB is also associated with other forms of
cancer, such as colon and breast cancer. Frequent
overexpression of MYB is observed in >80% of colon
carcinomas and such expression correlates with poor
prognosis (1,4–6). More than two-thirds of human
breast cancers, most of which require estrogen for
growth and survival, expresses high levels of estrogen
receptor (ERa) (7). A strong correlation has been
observed between high levels of MYB expression and
ERa positivity in breast cancer cells (8). Reports from
our laboratories have shown that MYB is essential for
the proliferation of ERa+, but not for most ERa,
breast cancer cells (9), which it can suppress proliferation
and apoptosis of such cells (10) and that MYB is required
for mammary tumorigenesis in several mouse models (11).
Expression of MYB has been shown to be regulated by
a transcriptional pausing mechanism (12–14). Genome
wide studies in human ES cells and in Drosophila
revealed that promoter proximal pausing is a widespread
phenomenon involved in the control of expression of im-
mediate early or developmentally regulated genes, and
that >30% of gene transcription is regulated by this mech-
anism (15). According to the current model, soon after
transcription initiation, RNA Polymerase II (Pol II)
becomes associated with two sets of protein complexes:
negative elongation factor (NELF) and DSIF [5,6-
dichloro-1b-D-ribofuranosylbenzimidazole (DRB) sensi-
tivity inducing factor]. The resultant transcriptional
pausing, in most genes, is induced within 25–50 nt down-
stream from the transcription start site. Phosphorylation
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of the C-terminal domain of RNA Pol II on Serine 2, and
of NELF and DSIF by P-TEFb [a complex of cyclinT1
and cyclin dependent kinase 9 (CDK9)] releases NELF
from the Pol II complex and allows Pol II to complete
the transcription (16).
In the case ofMYB, unlike most genes, pausing has been
detected at 1.7 kb downstream of the transcription initi-
ation site (13). Nuclear run-on assays have detected tran-
scription from the promoter and of sequences up to 1.7 kb
downstream in the first intron in several cell types even
when no or little MYB mRNA is expressed, indicating a
block in transcriptional elongation beyond this point. This
elongation block is overcome in cells that expressMYB and
conversely, is re-established when such cells differentiate
and lose MYB expression (12,17). The region where
this elongation block occurs contains a sequence that can
potentially form a stem–loop (SL) structure when
transcribed, associated with an adjacent poly (dT) stretch
(9,13,17). In the case of colorectal cancer, a significant fre-
quency of mutations is observed in this SL-dT region;
introducing these mutations into an elongation reporter
assay showed elevated levels of reporter gene activity,
that correlated with the sustained high level of MYB
mRNA in this type of cancer (17). However, such muta-
tions are rare in the case of breast cancer and therefore
unable to explain the high level of MYB expression in
ERa+ breast cancers. In this subtype of breast cancer,
MYB has emerged as a direct target of ERa (18), and
Drabsch et al. (9) have shown that ligand-bound ERa
acts to overcome the transcriptional elongation block
imposed by the regulatory SL-dT structure. Identifying
the factors or cofactors that act with ERa at this region
would provide insight into the mechanism of MYB gene
regulation in ERa+ breast cancer cells. Moreover, such
understanding is likely to provide insight into MYB regu-
lation in other cell types since as discussed above, expres-
sion is also regulated at the level of transcriptional
elongation in hematopoietic and colon cancer cells.
In this report, we show that functionally active tran-
scriptional elongation factor P-TEFb is required to
relieve the transcriptional attenuation mediated by the
SL-dT region between exons 1 and 2 of the MYB gene.
We find that ERa forms a complex with both CyclinT1
and CDK9 in MCF-7 cells, which is independent of the
presence of estrogen. Using chromatin-immuno-
precipitation (ChIP), we also show that upon b-estradiol
activation, ligand-bound ER recruits the P-TEFb complex
to a region near the regulatory SL-dT motif, and that
P-TEFb kinase activity is necessary for MYB transcrip-
tion to continue beyond this motif.
MATERIALS AND METHODS
Cell Culture
HEK293T cells were maintained routinely in DMEM high
glucose medium with 10% FBS, L-Glutamine and
Penicillin–Streptomycin (GIBCO/BRL, Grand Island,
NY, USA) at 37C incubator in the presence of 5%
CO2. MCF-7 cells were maintained regularly as a
monolayer in DMEM supplemented with 10% FBS,
L-Glutamine, 1mM sodium pyruvate, 0.1mM
non-essential amino acids (GIBCO/BRL, Grand Island,
NY), 10 mg/ml insulin (Sigma, St Louis, MO, USA) and
Penicillin–Streptomycin (GIBCO/BRL, Grand Island,
NY, USA). In order to observe the effect of estrogen,
MCF-7 cells were sub-cultured and maintained in a
phenol red free DMEM (GIBCO/BRL, Grand Island,
NY, USA) with 10% charcoal stripped serum (CSS;
GIBCO/BRL, Grand Island, NY, USA) and all other sup-
plements mentioned above for 48 h before 17-b-estradiol
(Sigma, St Louis, MO, USA) was added to the final con-
centration of 10 nM.
Antibodies
For ChIP assays, immunoprecipitation and western
blotting, anti-ERa HC20 rabbit polyclonal, anti-CDK9
C20 rabbit polyclonal, anti-CyclinT1 T-18 goat polyclonal
antibodies (Santa Cruz Biotechnology, USA) and mouse
monoclonal a-Tubulin antibody (Sigma, St Louis, MO,
USA) were used. Whole RNA pol II or Ser-2
phosphorylated RNA pol II was detected in ChIP assays
by anti-pol II 8WG1b mouse monoclonal or anti-RNA
pol II phospho CTDS2 rabbit polyclonal antibodies, re-
spectively (Abcam, UK).
Plasmid DNA, transfection and reporter gene assay
WT and SL-CAT constructs, used in this assay, were
described previously (11). In WT-CAT construct,
promoter, exon 1 and intron 1 sequences of c-MYB gene
were cloned upstream of the CAT. In order to generate the
SL deletion construct (SL-CAT), a stretch of 76 bp was
deleted from WT-CAT, which ends at the poly T stretch.
CyclinT1 and CDK9 and dominant negative CDK9 (DN–
CDK9; containing a point mutation at nucleotide 563
which converts Asp into Asn (29) were cloned in
pcDNA3.1 vector and expression of all proteins were con-
firmed by western blot. b-Actin-promoter-luciferase ex-
pression vector was used as an internal control in the
reporter assay obtained as a generous gift from C. Popa,
University of Queensland, Queensland, Australia. The
ERa expression construct pAER in which ERa c DNA
expression is driven by the human b-actin-promoter, was
obtained from the laboratory of Professor Christine
Clarke, Department of Medicine, University of Sydney.
Approximately 2.0 mg of total plasmid DNA was trans-
fected into HEK293T cells by using Lipofectamine 2000.
Briefly, 0.3 106 cells/well of a six-well plate was seeded
and transfections were carried out according to manufac-
turer protocol. After 24 h transfection, cells were incubated
with fresh DMEM supplemented with 10 nM estrogen for
16 h. Cells were lysed using 300 ml of lysis buffer/well of a
six-well plate and 20 ml of extract was used to estimate the
reporter gene activity using a CAT-ELISA assay kit
(Roche, Indianapolis, IN, USA). The same extracts were
utilized to estimate the control b-actin-promoter-luciferase
activity using LUC-assay kit (Promega, WI, USA).
Drug treatment
DRB, flavopiridol and anti-estrogen ICI 182780 were
dissolved in appropriate solvent as recommended by the
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manufacturer to make 1000-fold concentrated stocks.
MCF-7 cells were seeded at the density of 0.3 106 cells/
well of a six-well plate and incubated overnight at 37C.
Drugs were diluted in complete DMEM medium, added
to the plate and incubation continued for 4 h before
harvest. To estimate the effect of P-TEFb inhibitory
drugs in reporter gene assays, HEK293T cells were trans-
fected 24 h before drug treatment.
Immunoprecipitation and western blot
For transient transfection followed by immunopre-
cipitation experiments, 3 106 cells were seeded in a
100mm dish and transfected using Lipofectamine 2000 as
described above. Cell were harvested 48 h after transfection
and extracts were prepared with RIPA lysis buffer (50mM
Tris–Cl, pH8.3, 150mMNaCl, 1%NP40, 1%Deoxycholic
acid, 0.02% SDS, Bio-Rad, USA, 1mM PMSF, 1mM
DTT, 5% glycerol, Protease inhibitor cocktail, Roche
Applied Science). Extracts were centrifuged for 10min at
10 000 g and supernatants were used for immunopre-
cipitation. Extracts were incubated overnight at 4C, with
primary antibody or corresponding control IgG.
Immunocomplexes were precipitated by adding 20 ml
Protein A/G-Sephadex bead suspension (Santacruz
Biotech, USA). Beads were washed thrice with 1.0ml of
RIPA lysis buffer without protease inhibitor cocktail.
Immunocomplexes were boiled 5min with 20 ml of 2
SDS–PAGE sample buffer and analyzed by SDS–PAGE
gel followed by western blotting. Blots were incubated
with goat anti-mouse IgG coupled with horseradish
peroxide and the detections were carried out by enhanced
chemiluminescence reagent (Thermo Fischer Scientific,
USA). Images were recorded and analyzed by
CHEMIDOCK western imaging machine (Fischer
Biotech, USA).
RT-PCR
MCF-7 cells were treated with drug for 4 h and total RNA
extracted using an RNeasy kit (Qiagen, GmBH,
Germany). Approximately, 2.0mg of RNA was used to
synthesize cDNA for RT-PCR using Super ScriptR III
First-Strand Synthesis System (Invitrogen, USA). cDNA
was diluted 2-fold and 2 ml was used in the RT-PCR. In a
25 ml reaction mixture, 12.5 ml of 2 iQ-SYBER green
PCR mix (Bio-Rad, Hercules, CA, USA) was added to
12.5ml solution containing cDNA and 100 nM of PCR
primer. Real-time qPCR to measure MYB mRNA,
cyclophilin mRNA and 18S rRNA was carried out at
90C for 10 s, 56C for 15 s and 72C for 20 s for 40
cycles in a Rotor Gene 3000 machine (Corbett Research,
Sydney, Australia). Quantitative gene expression was
analyzed by the RotorGene 3000 software using
cyclophilin A as an internal control and 18S rRNA as a
loading control. The following sets of primers were used:
c-MYB forward, 50-GCC AAT TAT CTC CCG AAT
CGA-30; c-MYB reverse, 50-ACC AAC GTT TCG GAC
CGT A-30; cyclophilin A forward, 50-GGC AAA TGC
TGG ACC CAA CAC AAA-30; cyclophilin A reverse,
50-CTA GGC ATG GGA GGG AAC AAG GAA-30.
Human 18S rRNA forward: 50-GAG GTA GTG ACG
AAA AAT AAC AAT-30, 18S rRNA reverse: 50-TTG
CCC TCC AAT GGA TCCT-30 (19).
The real-time qPCR conditions to measure intronic
transcripts were 95C for 20 s, 95C for 10 s, 60C
for 20 s for 40 cycles. The primer sequences used to quan-
titate these PCR products were Pre-I forward: 50-
GAA ATC CTC GTC CGA ACT GTC AG-30,
Pre-I reverse: 50-GCG TGT GCT GCT GGG AAA G-
30; Post-III forward: 50-CCT CCG AAT CAC AGT
AGC-30, Post-III reverse: 50-TTC TGT CAA GGA
AAC AAA CC-30; Post-IV forward: 50-GTG GAG
GCT AGA CTA G:AA CC-30, Post-IV reverse: 50-ACC
CAG GAA CAA GCA ACC-30; cyclophilin A in-
tron forward: 50 ATT GTC CCT CTG CC-30 and
cyclophilin A intron reverse: 50- AGG AAA TCG CTC
TGT CCT CA-30.
ChIP assays
MCF-7 cells were grown in T175 flasks to 70–80%
confluence (3 107 cells). Cells were washed thrice
with PBS and incubated 20min at room temperature
with 1% formaldehyde. The cross-linking was stopped
by the addition of 0.1M glycine for 5min. Cells were
washed and resuspended in 1.0ml of lysis buffer (50mM
Tris–HCl pH 8.1, 1.0% SDS, 10.0mM EDTA and
protease inhibitor cocktail). Chromatin was sonicated
(Sonics & Materials, Inc., Newtown, CT, USA) for eight
cycles of 20 s sonication utilizing 40% efficiency and
2min incubation at 4C. Extracts were centrifuged for
16,000 g for 10min and the supernatant was diluted 1:10
with IP dilution buffer (20mM Tris–HCl, pH 8.1, 1.0%
TritonX-100, 2.0mM EDTA, 150mM NaCl). After
pre-clearing it with salmon sperm DNA (2 mg, SIGMA,
USA) and protein-Sepharose (45 ml of 50% slurry, Santa
Cruz Biotech, USA), the extract (100ml) was used
for immunoprecipitation for overnight at 4C with
1 mg of antibody and corresponding control IgG.
Immunoprecipitants were collected by adding 45 ml
protein A/G-Sepharose slurry and 2 mg salmon sperm
DNA after incubating 1 h at room temperature and
washed extensively once with TSEI (20mM Tris–HCl
pH 8.1, 0.1% SDS, 1.0% TritonX-100, 2.0mM EDTA
and 150mM NaCl), four times with TSEII (20mM Tris–
HCl pH 8.1, 0.1% SDS, 1.0% TritonX-100, 2.0mM
EDTA, 500mM NaCl, once with Buffer III (10mM
Tris–HCl, pH 8.1, 1mM EDTA, 1.0% deoxycholate,
1.0% NP-40, 0.25M LiCl) and thrice with TE. The
samples were eluted with 500 ml elution buffer (1.0%
SDS, 0.1M NaHCO3). Eluates were mixed with 0.2M
NaCl and kept overnight at 65C to reverse the cross
links. DNA samples were isolated by phenol/chloro-
form/isoamyl alcohol extraction and resuspended in
40 ml TE and analyzed by qPCR. Primers used for pS2
gene are forward: 50-GGC CAT CTC TCA CTA TGA
ATC ACT TCT GC-30, reverse: 50-GGC AGG CTC
TGT TTG CTT AAA GAG CG-30 and for Myb
intron-1 are forward: 50 AAA GAG CGT GGG TGG
AGA C 30 and reverse: 50GCA GTC GGG TTT CTC
TTC C 30.
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A functionally active P-TEFb complex is required for
ERa-mediated promotion of MYB transcriptional
elongation
As discussed above, differential expression of MYB in
several mammalian cell lines and lymphomas has been
shown to be due to blocking of transcriptional elongation
within the first intron (14,20,21). Previous data from our
laboratory established that in the case of ERa+ breast
cancer cells, ligand-bound ERa plays a critical role in
relieving this block (9). However, the factors or cofactors
which are specifically involved in this process are not
known. In general, the complex involved in relieving the
stalling of RNA Pol II is comprised of several proteins
besides P-TEFb, such as Brd4, HEXIM1 (and/or
HEXIM2), LARP7 and MePCE (16,22–28). Since
P-TEFb is known to play the central role in this
complex, and can be targeted by compounds that inhibit
its CDK9 component, we focused initially on the role of
this heterodimeric complex in relieving the transcriptional
pausing of MYB. To understand the regulatory process,
we have used a reporter gene construct where the human
MYB promoter, exon 1 and intron 1 sequences were
cloned upstream of a CAT reporter gene (WT-MYB
reporter construct) as described previously (17).
HEK293 cells were transiently transfected with the WT
MYB reporter construct along with ERa, cyclinT1 and
CDK9 in the presence or absence of estrogen. The
results shown in Figure 1A indicate that maximal
reporter activity requires co-expression of P-TEFb
(CyclinT1 and CDK9) and ERa in the presence of
estrogen. We also observed a dose-dependent effect of
P-TEFb expression on the activation of the WT-MYB
reporter construct. To demonstrate that these effects spe-
cifically reflected overcoming inhibition imposed by the
SL-dT motif, HEK293T cells were co-transfected with a
mutant reporter construct in which the SL-dT sequence
was deleted (SL-dT MYB reporter) (9,17). As expected,
the activity of this reporter gene was higher than that of
the WT-MYB reporter in the absence of ERa, P-TEFb or
estrogen, and it remained unresponsive to the
over-expression of P-TEFb, ERa and estrogen. To dem-
onstrate the requirement for catalytically active P-TEFb,
HEK293 cells were co-transfected with CyclinT1 and
either WT or dominant negative (‘kinase dead’) (29)
CDK9 (DNCDK9) to generate functionally active or
inactive P-TEFb complexes, respectively. With respect to
WT CDK9, a 3-fold down-regulation in WT-Myb
reporter gene activity was observed when cells were
co-transfected with DNCDK9, whereas under same con-
ditions activity of the mutant SL-dT MYB-reporter con-
struct remained unaffected (Figure 1B). To confirm these
findings we treated cells with the CDK9 inhibitor DRB for
4 h. In Figure 1C, the activity of the WT-Myb reporter
was down-regulated 3-fold in the presence of DRB
whereas no significant change was observed in the
activity of the mutant reporter construct. From these
results, we infer that functionally active P-TEFb
complex is required, and ERa and P-TEFb act
coordinately, to overcome the pausing of RNA Pol II in
the vicinity of the SL-dT region.
Next, we were interested to determine whether the
P-TEFb complex is also involved in the regulation of en-
dogenous MYB transcription in a more physiological
context. To this end, we used ERa+ breast cancer cells
which were treated with different concentrations of the
P-TEFb inhibitory drugs DRB or flavopiridol for 4 h.
Drug concentrations (2.5–25.0 nM flavopiridol and 2.5–
25.0mM DRB) and treatment time were chosen so that
drug-mediated effects on MYB transcription could be
observed without compromising cell viability. Expression
ofMYB was analyzed by qRT-PCR and compared to that
of the ‘housekeeping’ gene PPIA (cyclophilin A). In the
experiments shown in Figure 2A and B, we observed a
substantial dose-dependent down-regulation of cellular
MYB expression in MCF-7 cells treated with drugs
which varied from 6-fold to 10-fold with DRB and
flavopiridol, respectively. In contrast, no effect was
observed on cyclophilin A expression. It is also important
to note that the effective concentrations of flavopiridol
required to down-regulate MYB expression are about
1000-fold lower than those of DRB. This observation
correlates well with the minimal P-TEFb inhibitory con-
centrations for those two drugs determined earlier by
Chao and Price (30). To further confirm the role of
P-TEFb in relieving transcription attenuation, we over-
expressed DNCDK9 in MCF-7 cells together with
GFP. GFP-positive cells were isolated 48 h after transfec-
tion and used to determine the effect of functionally
inactive P-TEFb on endogenous MYB gene expression.
In Figure 2C, ectopic expression of DNCDK9 down-
regulated the expression of MYB in comparison to the
untransfected control while having little effect on
cyclophilin A expression. In contrast, a substantial activa-
tion, more than 5-fold, was observed upon
over-expression of WTCDK9, suggesting that this factor
may normally be rate-limiting. Collectively, from the
above data, we conclude that CDK9 activity is required
for ERa-mediated relief of the block to MYB transcrip-
tional elongation.
Estrogen depletion and drug-mediated inhibition of
the P-TEFb complex blocks transcription beyond the
SL-dT region
According to the general model of transcription pausing,
RNA Pol II initiates transcription and pauses within 30–
50 nt downstream from the transcription start site (16,31).
It has been demonstrated that the generation of the result-
ant short transcripts is not inhibited by P-TEFb inhibitory
drugs, such as DRB or flavopiridol, but that elongation
leading to the synthesis of longer transcripts is inhibited
(32,33). In the case of the MYB gene, however, transcrip-
tional pausing occurs at/near the SL-dT motif which is
about 1.7 kb downstream of the initiation site, as shown
by nuclear run-on assays (9,17). If P-TEFb is essential for
the synthesis of the complete MYB transcript, we would
predict that inhibition of this complex would significantly
reduce the synthesis of pre-mRNA that extends beyond
this SL-dT region, without significant change in the level
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of the shorter transcripts that are blocked at/before this
region.
To measure transcription upstream and downstream
of the SL-dT motif, we designed several RT-PCR
primers based on DNA sequence before and after the
SL region, as depicted in Figure 3A. The qRT-PCR data
of Figure 3C show that addition of estrogen not only sig-
nificantly enhanced the synthesis of mature MYB mRNA
(detected by exon8/9-based primers), but also increased
the level of intronic pre-mRNA transcripts beyond the
SL-dT region several-fold, as detected by Post-III and
Post-IV primers (Post-PCR product). In contrast, there
was little change in the levels of transcripts upstream of
the SL-dT motif (detected by Pre-I primers,) or of exonic
or intronic cyclophilin A transcripts. These data are com-
pletely consistent with our previous data obtained using
nuclear run-on assays (9) and thus validate the use of this
qRT-PCR assay.
Next, MCF-7 cells were treated with DRB for 4 h and
RNA was isolated to determine the expression of the
various transcripts by qRT-PCR, which was then
normalized to the levels in untreated cells. This revealed
a substantial down-regulation of the synthesis of
mature MYB mRNA (5-fold) and of post-SL-dT tran-
scripts detected by primers Post-III and Post-IV (5- to 7-
fold) in the drug-treated cells with respect to the untreated
control (Figure 3D). However, little difference was seen
in the levels of PCR products generated by the Pre-I
primer set, located upstream of the SL-dT region or in
the level of cyclophilin transcript synthesis, detected by
intron based primers. A difference in the levels of Pre-
and Post-PCR products was also observed when we used
another set of primers (EV-I for Pre and EV-III
and EV-IV for Post) for analysis by non-quantitative
PCR. A clear down-regulation was observed in the level
post-PCR products detected by EV-III and EV-IV in
the presence of drug whereas a only minor change
was observed in the Pre-product identified by EV-I
(Supplementary Figure S1). Therefore, we conclude
that transcription pausing either induced by
inhibiting P-TEFb complex or relieved by addition of
estrogen strongly correlates with the absence or
A
B C
Figure 1. P-TEFb and an intact SL region of intron I are required for the transcriptional regulation of MYB reporter constructs by estrogen.
(A) HEK293 cells are transfected (0.5 106/well of six-well plate) with 1.0 mg of WT-MYB CAT (Left panel) or 1.0 mg SL-MYB CAT construct
(Right panel) along with 0.1 or 0.2 mg each of CyclinT1 and CDK9 and 10 ng pCMV b-actin-promoter-luciferase expression plasmid. After 24 h, cells
were incubated with fresh medium supplemented with or without 10 nM estradiol for 16 h. (B) Transient transfections in HEK293 cells were carried
out, as described above, in the presence of either WT P-TEFb (0.1 mg each of CyclinT1 and CDK9) or dominant negative CDK9 expression construct
(0.1 mg) along with WT P-TEFb complex before adding estrogen to the medium. (C) After transient transfection, cells were either exposed to estrogen
or to 25 mM DRB as indicated for 16 h. In each case, CAT activity was normalized to b-actin-promoter-Luc activity as an internal control.
Experiments were done in triplicate and repeated at least thrice.
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presence, respectively, of intronic transcription immedi-
ately downstream of the regulatory SL-dT region, but
not with apparently constitutive transcription upstream
of this region.
ERa forms a complex with P-TEFb
We have shown that estrogen is required for MYB tran-
scriptional elongation (Figure 3B) and that ERa is re-
cruited to chromatin near the SL-dT motif (9), while the
data shown in Figures 1 and 2 have now established that
functionally active CDK9, and thus probably P-TEFb, is
required to relieve transcriptional attenuation. Taken
together, these observations suggested that ERa and
P-TEFb act in concert to overcome the block to MYB
transcriptional elongation, and raise the possibility that
ERa may actually recruit P-TEFb. Indeed, an association
between endogenous ERa and CyclinT1 has previously
been shown in MCF-7 cells (34). We therefore wished to
determine whether ERa associated with the P-TEFb
complex. First, HEK293T cells were co-transfected
either with CDK9 and ERa or CyclinT1 and ERa, and
extracts were used for co-immunoprecipitation experi-
ments. The data shown in Figure 4A indicate that
anti-ERa antibody can pull down both CDK9 and
CyclinT1. Complex formation of ERa with CDK9
and CyclinT1 was confirmed by using anti-CDK9 and
anti-CyclinT1 antibody to co-precipitate ERa. In order
to confirm the existence of this complex with endogenous
proteins, whole cell extracts prepared from MCF-7 cells
were subjected to immunoprecipitation with the same
antibodies. Additionally, to examine the role of estrogen
in complex formation, the cells were grown either in a
regular medium (RGM control in Figure 4B), in a
hormone-free serum supplemented medium (CSS) for
48 h, or overnight in CSS medium supplemented with
estrogen. Using anti-CyclinT1 and anti-ERa antibody,
we detected CDK9 in immunoprecipitates from all three
treatments, and moreover, the levels of co-precipitated
proteins were independent of the presence or absence of
hormone (Figure 4B, left panel and Figure 4C, right
panel). These observations were confirmed by performing
additional immunoprecipitations with anti-CyclinT1 and
anti-ERa antibodies. We could detect the presence of
CyclinT1 (Figure 4C, left panel) and ERa (Figure 4B,
right panel) in the immunocomplexes formed by the
anti-ERa and anti-CyclinT1 antibodies, respectively, and
moreover, no significant difference in the levels of
co-precipitated proteins were detected with or without
estrogen. These data strongly suggest that at least a
fraction of ERa forms a complex with P-TEFb as all
three proteins (ERa, CyclinT1 and CDK9) can be
co-immunoprecipitated in pair-wise combination, and
that complex formation is independent of the presence
of estrogen. The latter observation differs to some extent
from that of Wittmann et al. (34) who detected enhanced
CyclinT1–ERa interaction in the presence of estrogen
using a cell-free GST pull-down assay.
The P-TEFb complex is specifically recruited to the
regulatory region of the MYB gene through ERa
Recruitment of the P-TEFb complex at the pausing site is
one of the most critical steps in resuming transcription. In
the case of HIV, the virus-encoded Tat protein recruits
this complex to the TAR RNA sequence to allow tran-




Figure 2. Functionally active P-TEFb complex is selectively required
for MYB expression. CDK9 inhibitors DRB and flavopiridol
down-regulate the endogenous MYB gene expression. MCF-7 cells
grown in regular growth medium (RGM) were treated with (A) DRB
and (B) flavopiridol for 4 h. Cells were harvested and expression of
MYB and cyclophilin A (Cyclo) was measured by qRT-PCR. (C)
Over-expression of DN CDK9 inhibits endogenous MYB gene expres-
sion. MCF-7 cells were transfected with WT CDK9 or DN-CDK9
along with pCMV-GFP and treated with 10 nM estrogen. Cells were
harvested 16 h after the hormone treatment and GFP-positive cells were
isolated by FACS. RNA samples were isolated from the GFP-positive
cells and used in qRT-PCR. In all experiments, relative expression of
each gene was normalized by 18s Ribosomal RNA expression values as
a control. Each experiment was done in duplicate and repeated at least
twice.
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complex is also recruited to cellular target genes by tran-
scription factors, such as NFkB, MyoD, c-Myc or chro-
matin remodeling proteins such as Brd4, in part, by
protein–protein interactions (25,36). In MCF-7 cells, pub-
lished data from our laboratory (9) and global
ChIP-on-chip or ChIP-seq analyses (37,38) have shown
in vivo ERa binding in a region close to the SL-dT motif
in the presence of estrogen. We were interested to know
whether the P-TEFb complex is also recruited to this
region and whether, given that P-TEFb forms a complex
with ERa, the latter is required for its recruitment. To do
this, we used ChIP followed by qPCR with primers that
amplify 419 bp ofMYB intron1 sequence including 181 bp
upstream and 166 bp downstream from the 72 bp SL-dT
region, as described previously (9). As a control for an
estrogen-regulated gene, we used primers designed to
amplify the promoter segment of the pS2 gene, which
contains a well-defined ERa-binding site (39). As
expected, qPCR analysis of ChIP samples generated
using ERa-specific antibody detected binding (several
fold above the control IgG) to the regulatory region
of the MYB gene and to the pS2 promoter element
(Figure 5A and B). Significantly, we also detected the
presence of both CyclinT1 and CDK9 when antibodies
to each of these proteins and the same MYB intron1
primers were used in ChIP assays. Somewhat surprisingly,
we did not detect CDK9 or CyclinT1 association with the
pS2 promoter, indicating a selective recruitment of these
P-TEFb components to particular sites (Figure 5C). Since
co-immunoprecipitation suggested complex formation of
P-TEFb with ERa, we next wished to determine the role
of ERa in the recruitment of the components of this
complex to the MYB SL-dT region. Therefore, ChIP
assays using antibodies against ERa, CyclinT1 and
CDK9 were carried out on MCF-7 cells that had been
incubated in estrogen-free medium for 48 h. Results pre-
sented in Figure 6A show negligible binding of ERa to the
Myb-regulatory region and no significant accumulation of
CDK9 or CyclinT1 under these conditions, but subse-
quent exposure to 10 nM estrogen for 16 h showed a sig-
nificant recovery of the ERa binding to the MYB
regulatory region. In parallel to ERa binding, a significant
increase in the binding of CyclinT1 and CDK9 was




Figure 3. Synthesis of transcripts beyond the SL-region strongly correlates with the estrogen mediated stimulation or drug mediated down-regulation
of endogenous MYB gene. Diagrammatic representation of human MYB (A) and cyclophilin A (B) genes. In the case of MYB, the position of the SL
and poly dT sites are shown. Positions of intron based primers are indicated as Pre-I, Post-III and Post-IV. Full-length MYB transcripts are detected
by MYB exon primer recognizes the sequence of exon8/9 region. Cyclophilin A full-length transcripts are detected by Cyclo Exon primers which
recognize exon 5. (C) Ligand bound ERa relieves transcriptional attenuation of MYB gene expression. MCF-7 cells were kept 48 h in DMEM
medium supplemented with CSS and incubated 2 h with 10 nM estrogen. The difference in gene expression in the presence of estrogen is shown as a
fold change in comparison to the non-estrogen-treated cells. (D) DRB-mediated down-regulation of MYB transcription is associated with significant
reduction in the synthesis of transcripts beyond the SL-dT region. MCF-7 cells were treated with 25 mM DRB for 4 h and synthesis of transcripts was
estimated by qRT-PCR. Gene expression in the presence of drug was compared with the untreated control cells.
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response to estrogen in each case is actually quite rapid, as
strong binding was also seen after 1 h (Supplementary
Figure S2). To establish further the role of ERa in the
recruitment of P-TEFb complex, we used the drug
Fulvestrant/ICI182780 which not only blocks nuclear lo-
calization of this receptor, but also expedites its
proteasome-mediated degradation (21). ChIP assays
were performed using extracts prepared from MCF-7
treated with 100 nM Fulvestrant for 16 h (Figure 6C). A
significant down-regulation (about 3- to 4-fold) of both
ERa and P-TEFb binding was observed in the drug-
treated sample. Note that Fulvestrant did not affect the
total amounts of CDK9 and cyclinT1 in these cells
(Supplementary Figure S3). We also performed a
recovery experiment where cells were returned to
Fulvestrant-free medium for 24 h after treatment as
above. ChIP assay of this extract showed a significant
re-accumulation of both ERa and P-TEFb complex
binding (Figure 6D). Collectively, from the above
results, we conclude that P-TEFb is recruited to the
MYB-regulatory region as part of the complex formed
with ligand-bound ERa.
P-TEFb recruitment to the MYB attenuation region
results in enhanced Pol II phosphorylation
Phosphorylation of the C-terminal domain (CTD) of
RNA Pol II on its serine 2 residue is required order
to resume transcriptional elongation after promoter-
proximal pausing. Of the two serine residues at positions
2 and 5 of the CTD, CDK9 preferentially phosphorylates
Ser-2 (40). It was also reported that estrogen-dependent
regulation of transcription is dominated by the changing
phosphorylation of RNA Pol II rather than recruitment of
Pol II holoenzyme (41). We therefore wanted to determine
the CTD phosphorylation status in the presence or
absence of estrogen by ChIP assay, using an antibody
that can detect the Ser-2 phosphorylated RNA Pol II.
To detect the level of phosphorylated Pol II at the tran-
scription attenuation region of the MYB gene, samples
from ChIP assays were analyzed by RT-PCR using the
primer set described earlier. As observed in Figure 7A,
Ser-2 phosphorylation of Pol II was significantly
up-regulated (5- to 6-fold) after addition of estrogen,
which is consistent with phosphorylation by CDK9. At
the same time, the amount of total polymerase bound to
that site was at least 2-fold down-regulated which was
estimated by an antibody recognizing total Pol II. We
suggest that the decrease in total polymerase at the attenu-
ation site after estrogen addition is most likely because of
the mobilization of stalled polymerase after estrogen
addition and P-TEFb recruitment. Most importantly,
the large increase in Ser-2 phosphorylation correlates
well with the recruitment of P-TEFb complex to the at-
tenuation region of the MYB gene (Figures 5C and 6B).




Figure 4. Complex formation between CyclinT1, CDK9 and ERa. (A) Expression plasmids encoding CyclinT1, CDK9 and ERa were co-transfected
into HEK293 cells and immunoprecipitated (IP) with the indicated primary antibodies and the resultant complexes were analyzed by western blotting
(WB) using the indicated secondary antibodies. (B) and (C) Identification of complex formation by endogenous proteins. MCF-7 cells were grown in
estrogen free (CSS), 10 nM estrogen added and in regular growth medium (control). Extracts, prepared from cells grown in the three different
conditions, were used for immunoprecipitation (IP) with anti-CyclinT1 in (B) and anti-ERa in (C). Complexes were analyzed by WB using the
antibodies indicated under each panel. In each case, 10% of the total cell extract was loaded for comparison and is labeled ‘In’ (input).
Nucleic Acids Research, 2012, Vol. 40, No. 13 5995
 at U






Ser-2 phosphorylated Pol II in proximity of promoter and
transcription start site. In the presence of estrogen, we
found an enrichment of RNA Pol II at the proximal
promoter region of pS2. Although we noticed a significant
basal level of Ser-2 phosphorylated Pol-ll, no further en-
richment of Ser-2-phosphorylated Pol II was observed
after estrogen stimulation (Figure 7B). This observation
matches well with the data in Figure 5 showing a very low
basal level of P-TEFb complex at the actively transcribing
pS2 gene. This is reinforced by comparison of the amount
of Ser-2 phosphorylation of Pol II in both genes with




Figure 5. ChIP assays detect ERa and P-TEFb components in the attenuation region of the MYB gene. (A,B) ERa binding to the MYB intron-I
attenuation region and the pS2 promoter. In total, 0.25, 0.5 or 1.0 mg of anti-ERa antibody, no antibody (mock) or control IgG (1.0 mg) was added to
MCF-7 cell extracts and ChIP assays were performed as described in ‘Materials and Methods’ section. (C) P-TEFb complex components are
selectively recruited to the MYB intron-1 region. Anti-CyclinT1 and anti-CDK9 antibody (0.25 or 0.5 mg) or 0.5 mg of IgG was added to the
MCF-7 extract for ChIP assays. The amount of DNA bound to ERa, CyclinT1 and CDK9 was detected by qPCR using MYB intron- and pS2
promoter-specific primers and the results are plotted as percentage of input.
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a 10-fold increase in the proportion of Ser-2-
phosphorylated Pol II in the presence of estrogen at the
MYB attenuation site, whereas a small decrease was
apparent at the pS2 promoter (Figure 7C).
DISCUSSION
Previous studies from our laboratory have shown that
MYB is required for the proliferation of breast cancer
cells. In these and other cells,MYB expression is regulated
by transcriptional pausing in the first intron, which in turn
is relieved by binding of the estrogen–ERa complex. We
wished to investigate the mechanisms involved and, in par-
ticular, to know whether the P-TEFb complex, known to
be involved in stimulating promoter-proximal transcrip-
tional elongation, is also required here. Using CDK9 in-
hibitory drugs and dominant negative CDK9, we have
demonstrated here that functionally active P-TEFb
complex is indeed required to overcome the transcrip-
tional block imposed by the previously described SL-dT
motif in intron 1. Our data also strongly suggest that a
tripartite complex is formed between ERa, CyclinT1 and
CDK9. In the presence of hormone, the ligand-bound
complex is recruited to the transcriptional pausing site,
where its ability to phosphorylate RNA Pol II is essential
for the resumption of transcriptional elongation as
illustrated in the model shown in Figure 8. We will
consider each of these key findings below.
We have shown that transcription of MYB in estrogen-
dependent breast cancer cells is directly regulated by the
P-TEFb complex. First generation Cdk9 inhibitors, such
as DRB and flavopiridol, as well as ectopic expression of a
dominant-negative CDK9, result in significant
down-regulation of MYB transcription when cells are
exposed to these agents. Critically, RT-PCR showed that
this is a result of re-imposition of a transcriptional block
imposed by the SL-dT attenuation motif, which is
normally overcome by ERa. Moreover, in Figure 3A,
we observed a very low IC50 for inhibition of MYB ex-
pression in MCF-7 cells of 3–4 nM when exposed for 4 h.
However, concentrations of flavopiridol of up to 300 nM
are required for substantial inhibition of total Pol II tran-
scription as determined by nuclear run-on assays (30).
Thus, we suggest that because of the stringent requirement
for transcriptional elongation, and hence for P-TEFb
activity, imposed by the SL-dT attenuation motif, MYB
A B
B D
Figure 6. Recruitment of the P-TEFb complex to the MYB regulatory region is dependent on ligand-bound ERa. (A,B) MCF-7 cells were cultured
in estrogen-free medium for 48 h, following which 10 nM estrogen or vehicle was added for a further 16 h. Extracts prepared from cells cultured in
both conditions were used to perform ChIP assays using (A) anti-ERa antibody (1.0mg), (B) anti-CyclinT1 (0.5 mg) and anti-CDK9 (0.5 mg)
antibodies and corresponding control antibody (IgG) or no antibody (mock). The amount of binding was estimated by qPCR and expressed as
percent input. (C,D) MCF-7 cells were incubated with 10 mM ICI 182780 for 16 h (ICI). Half of these cells were harvested and the remaining cells
were incubated in fresh drug-free growth medium for 24 h (Recovery). An extract prepared from MCF-7 cells grown in regular growth medium
(RGM) was used as control. Extracts of harvested cells were used for ChIP assays using (C) anti-ERa (1.0 mg), (D) anti-CyclinT1 (0.5 mg) or
anti-CDK9 (0.5 mg) antibodies as indicated.
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expression is particularly sensitive to inhibition of tran-
scriptional elongation and CDK9 activity. This parallels
the heightened sensitivity of HIV to flavopiridol (30),
which is likely to reflect the requirement for Tat recruit-
ment of P-TEFb for elongation of HIV transcripts
through the TAR motif (42).
The ChIP assay data obtained in the absence or
presence of estrogen or Fulvestrant treatment indicated
that recruitment of the P-TEFb complex by ERa to the
attenuation region in MYB intron 1 depends upon the
binding of estrogen to the receptor. Since our
co-immunoprecipitation data show that formation of the
ERa–CyclinT1–CDK9 complex is independent of the
presence of hormone, this implies the hormone-dependent
step is DNA binding by ERa itself. Analysis of
ChIP-on-chip and ChIP-seq data (37,38) shows a recep-
tor-binding region within a span of 298 bp located
200 bp upstream from the beginning of the SL-dT at-
tenuation motif. Indeed, we have confirmed ERa
binding in the vicinity of this motif previously (9) and in
the present report (Figures 5–7). While there are no con-
sensus full-length ERa-binding elements (EREs) within




Figure 7. Estrogen stimulation selectively induces P-TEFb
complex-driven Ser-2 phosphorylation of RNA Pol II in the MYB at-
tenuation site. ChIP assays were performed with MCF-7 extract from
cells grown either in the absence or presence of estrogen using
anti-RNA Pol II antibody or anti-RNA Pol II CTD phospho Ser-2
Figure 7. Continued
antibody. The amount of total RNA Pol II and Ser-2 phospho-Pol II
bound was detected by qPCR using MYB intron-1-specific primers (A)
and pS2 promoter-specific primers (B), and expressed with respect to
the input. These data are also plotted (C) to show the proportion of
Ser-2 phosphorylated RNA Pol II compared with the total RNA Pol II
present at the pS2 promoter and MYB intron-I pausing site in the
presence or absence of estrogen.
Figure 8. Model for estrogen-mediated relief of MYB transcriptional
attenuation. Transcription is paused at the SL-dT region in the absence
of estrogen in MCF-7 cells where Pol II is hypophosphorylated at
Ser-2. Upon estrogen stimulation, the ERa–CyclinT1–CDK9 tripartite
complex is recruited to the attenuation (SL-dT) region; this, in turn,
phosphorylates the Ser-2 residue of RNA Pol II to allow resumption of
elongation.
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CA) is located very close to the polydT sequence and
another (TGACC) is within the 298 nt in vivo-binding
region. However, introducing mutations into each of
these sites individually within our WT-Myb elongation
reporter construct had no effect on the estrogen
response of this construct (our unpublished results).
Taken together, these observations suggest that ERa
binds either to a highly divergent motif or via tethering
by another transcription factor (43). Distinguishing
between these alternatives will require further study.
It is worth commenting on the fact that while we
observed selective recruitment of Cyclin T1 and CDK
upon ER binding to the MYB intronic region, we did not
observe recruitment of this P-TEFb complex to the pS2
promoter. In contrast, Wittmann et al. (34) reported the
estrogen/ERa-stimulated recruitment of CyclinT1 to the
pS2 promoter. However, in our experiments, MCF-7 cells
were treated with estrogen for 12 h rather than the shorter
times (45 and 90min) used by Wittmann et al. One possi-
bility is that in the initial stage of estrogen/ERa-stimulated
pS2 gene expression, CyclinT1 is recruited to the promoter
as a part of an ERa–CyclinT1 complex, but that it may
rapidly dissociate as transcription continues, resulting in a
low/undetectable steady-state level. In the case of theMYB
intronic pausing region, high levels of P-TEFb may be con-
tinuously required to maintain elongation, by promoting
Ser-2 phosphorylation of the Pol II CTD, in the presence of
the attenuating effect of the SL-dT motif. Our data
showing (i) accumulation of Pol II near the attenuation
region and (ii) the strong stimulation by estrogen of Ser-2
CTD phosphorylation of Pol II bound to this region,
compared to in each case to the pS2 promoter, are
entirely consistent with such a notion.
Our recent work has shown an essential role forMYB in
the proliferation of human breast cancer cells in vitro and
in vivo (9,11), and that it is required for mammary tumori-
genesis in (at least) two murine transgenic breast cancer
models (11). Given these observations, and that MYB
knockdown potentiates differentiation and apoptosis
(10), targeting of MYB in breast cancer is a potentially
attractive therapeutic approach. Moreover, MYB’s wide-
spread involvement in other major cancers, such as colon
carcinoma and leukemia, would further enhance the utility
of a general strategy for targeting MYB. The fact that
MYB expression is largely regulated at the level of tran-
scriptional elongation suggests inhibition of this process
may be an effective and possibly selective approach (1).
The data reported here show a stringent requirement for
CDK9 activity to maintain estrogen/ERa-dependent
MYB expression and identify inhibition of this kinase
with existing compounds as to some extent selectively
down-modulating MYB expression. We might therefore
predict that MYB-expressing ERa+ breast cancer cells
might be more sensitive to CDK9 inhibitors than ERa/
MYBve cells. Indeed, preliminary studies have shown
that the IC50 for flavopiridol in an MCF-7 cell survival
assay is 15 nM, while viability of ERa/MYB
MDA-MB-231 cells is unaffected by that concentration
(Z. Talaash, our unpublished observations). The extent
to which such effects are, in fact, due to MYB inhibition
and whether MYB expression can be selectively
suppressed by CDK9 inhibition in other MYB-dependent
cancer types will require further investigation.
While this manuscript was under revision, Stadhouders
et al. (44) reported that P-TEFb was recruited in mouse
erythroid cells to a site in Myb intron 1 that probably
corresponds to the SL-dT attenuation region mentioned
here. They also reported that transcriptional elongation
was strongly inhibited by Cdk9 inhibitors as we have
found here.
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